Can pharmacogenomics improve malaria drug policy?
Open Access
- 1 November 2011
- journal article
- research article
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 89 (11) , 838-845
Abstract
Coordinated global efforts to prevent and control malaria have been a tour-de-force for public health, but success appears to have reached a plateau in many parts of the world. While this is a multifaceted problem, policy strategies have largely ignored genetic variations in humans as a factor that influences both selection and dosing of antimalarial drugs. This includes attempts to decrease toxicity, increase effectiveness and reduce the development of drug resistance, thereby lowering health care costs. We review the potential hurdles to developing and implementing pharmacogenetic-guided policies at a national or regional scale for the treatment of uncomplicated falciparum malaria. We also consider current knowledge on some component drugs of artemisinin combination therapies and ways to increase our understanding of host genetics, with the goal of guiding policy decisions for drug selection.Keywords
This publication has 42 references indexed in Scilit:
- Application of Pharmacogenomics to Malaria: A Holistic Approach for Successful ChemotherapyPharmacogenomics, 2009
- Effect of Concomitant Artesunate Administration and Cytochrome P4502C8 Polymorphisms on the Pharmacokinetics of Amodiaquine in Ghanaian Children with Uncomplicated MalariaAntimicrobial Agents and Chemotherapy, 2008
- South Africa: from species cradle to genomic applicationsNature Reviews Genetics, 2008
- From diversity to delivery: the case of the Indian Genome Variation initiativeNature Reviews Genetics, 2008
- ANTIMALARIAL DRUG RESISTANCE, ARTEMISININ-BASED COMBINATION THERAPY, AND THE CONTRIBUTION OF MODELING TO ELUCIDATING POLICY CHOICESThe American Journal of Tropical Medicine and Hygiene, 2004
- Identification of human cytochrome P 450 s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro dataEuropean Journal of Clinical Pharmacology, 2003
- Amodiaquine Clearance and Its Metabolism to N-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe SubstrateThe Journal of Pharmacology and Experimental Therapeutics, 2002
- The T76 mutation in the pfcrt gene of Plasmodium falciparum and clinical chloroquine resistance phenotypes in Papua, IndonesiaPathogens and Global Health, 2001
- Role of hepatic metabolism in the bioactivation and detoxication of amodiaquineXenobiotica, 1995
- The mechanism of bioactivation and antigen formation of amodiaquine in the ratBiochemical Pharmacology, 1992